Orrick Advises MorphoSys on Equity Participation Transaction with HIBio

July.08.2022

Orrick advised German biopharmaceutical company MorphoSys (FSE: MOR; NASDAQ: MOR) on its equity participation transaction with biotech company Human Immunology Biosciences (HIBio). The Orrick team advising MorphoSys was led by Thomas Schmid and David Ruff, and included Jay Schau and Jamie Kamen.